Welcome

Investor Relations

Corporate Profile

Novavax, Inc. is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Our recombinant nanoparticles and adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.

Latest Investor Presentation Latest Earnings Presentation
(Updated September 9, 2021) (Updated November 4, 2021)
Stock Information
NASDAQNVAX
NASDAQNVAX
Recent News
Nov 24, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the...

Nov 23, 2021

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate...

Nov 18, 2021

Positive results from the first co-administration study of a SARS-CoV-2 vaccine candidate and an approved influenza vaccine have been published in The Lancet Respiratory Medicine. The previously...

View All Press Releases

Events
Thursday, November 4, 2021
4:30pm - 5:30pm EDT
Wednesday, September 29, 2021
8:40am - 9:10am EDT

View All Events